

# The insulin-like growth factor system in multiple myeloma: prognostic and therapeutic potential

Oncotarget

7, 48732-48752

DOI: [10.18632/oncotarget.8982](https://doi.org/10.18632/oncotarget.8982)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1324-1334.	1.9	26
2	Mechanisms of Resistance in Multiple Myeloma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 251-288.	0.9	20
3	IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis. <i>Experimental Cell Research</i> , 2017, 361, 9-18.	1.2	21
4	Emerging immune targets for the treatment of multiple myeloma. <i>Immunotherapy</i> , 2018, 10, 265-282.	1.0	19
5	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
6	NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3503.	1.8	14
7	The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. <i>Frontiers in Oncology</i> , 2018, 8, 566.	1.3	39
8	Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. <i>Frontiers in Immunology</i> , 2017, 8, 1936.	2.2	39
9	Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer – from Basic Research to Potential Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4915.	1.8	49
10	Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. <i>Antibodies</i> , 2019, 8, 34.	1.2	10
11	Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e17680.	0.4	8
12	Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. <i>British Journal of Haematology</i> , 2019, 184, 578-593.	1.2	18
13	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 489.	1.1	3
14	Novel conjugates of endoperoxide and 4-anilinoquinazoline induce myeloma cell apoptosis by inhibiting the IGF1-R/AKT/mTOR signaling pathway. <i>BioScience Trends</i> , 2020, 14, 96-103.	1.1	0
15	Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy. <i>Journal of Lipid Research</i> , 2020, 61, 611-635.	2.0	150
16	Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?. <i>Advances in Hematology</i> , 2021, 2021, 1-7.	0.6	11
17	Diabetes, but not pre-diabetes, is associated with shorter time to second-line therapy and worse outcomes in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2785-2792.	0.6	2
18	Identification of Candidate Biomarkers and Prognostic Analysis in Colorectal Cancer Liver Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 652354.	1.3	13

#	ARTICLE	IF	CITATIONS
19	<i>MiR-148a</i> inhibits oral squamous cell carcinoma progression through ERK/MAPK pathway via targeting IGF-IR. <i>Bioscience Reports</i> , 2020, 40, .	1.1	11
20	Bone marrow adipocytes and multiple myeloma. <i>Oncogematologiya</i> , 2019, 14, 60-75.	0.1	1
21	Microenvironment drug resistance in multiple myeloma: emerging new players. <i>Oncotarget</i> , 2016, 7, 60698-60711.	0.8	137
22	PK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. <i>Oncotarget</i> , 2017, 8, 39185-39197.	0.8	15
23	Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma. <i>Ecancermedicalsecience</i> , 2020, 14, 1088.	0.6	7
24	The overexpression of IGF-1 is a poor prognostic factor in multiple myeloma. , 2019, 18, 42-49.	0.3	1
28	Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple. <i>CES Medicina</i> , 2021, 35, 284-295.	0.1	0
29	Evaluation of Serum Levels of Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Patients With Colorectal Cancer: A Case-Control Study. <i>Cureus</i> , 2021, 13, e19881.	0.2	2
30	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	9
32	Obesity and multiple myeloma: Emerging mechanisms and perspectives. <i>Seminars in Cancer Biology</i> , 2023, 92, 45-60.	4.3	7
33	Anti-Angiogenic Activity of Drugs in Multiple Myeloma. <i>Cancers</i> , 2023, 15, 1990.	1.7	2